Clinical trials: Circulating Tumor Cell;, open to volunteers
Non Small Cell Lung Cancer, Circulating Tumor Cell
CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC
clinical trial The goal of this clinical trial is to learn whether the treatment of advanced non-small cell lung cancer with EGFR-TKIs, when combined with bevacizumab in the presence of positive circulating tumor cells in the…
- Conditions
- Non Small Cell Lung Cancer, Circulating Tumor Cell, EGF-R Positive Non-Small Cell Lung Cancer
- Trial name
- NCT06557096
- Testing
- Osimertinib 80 MG, Bevacizumab
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Breast Cancer
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA
CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.
- Trial name
- GALIA (NCT07418125)
- Testing
- Liquid biopsy
- Where
- Slovenia
- Volunteers
- 130 people
- Sponsor
- Institute of Oncology Ljubljana
Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
- Trial name
- NCT06070012
- Testing
- Tebentafusp
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Diwakar Davar
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
The goal of this adaptive, interventional study is to assess the efficacy and safety of osimertinib-based adaptive treatment based on ctDNA dynamic monitoring in locally advanced or metastatic EGFRm NSCLC participants with ctDNA…
- Trial name
- NCT07058519
- Testing
- Osimertinib-based adaptive treatment, Osimertinib 80 MG
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Neoadjuvant immunotherapy has become the standard perioperative treatment in lung cancer, but its effective predictive biomarkers are lacking.
- Trial name
- NCT05965557
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Hepatocellular Carcinoma, Circulating Tumor Cell
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
On the basis of previous retrospective studies, the Task Force will further optimize the CTCs longitudinal surveillance model and initially validate the subclonal origin (CTC-DNA) of recurrent/metastatic foci derived from CTCs at…
- Conditions
- Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery
- Trial name
- NCT06317896
- Testing
- circulating tumor cells
- Where
- 3 sites in China
- Volunteers
- 82 people
- Sponsor
- Zhujiang Hospital
Lung Cancer, Circulating Tumor DNA
NSCLC Liquid Biopsies and Exhaled VOC
The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for…
- Trial name
- NCT06707519
- Where
- Canada
- Volunteers
- 210 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence
Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT
This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence, Progression of Bladder Cancer, Transurethral Resection of Bladder Tumor
- Trial name
- NCT07589413
- Testing
- Measurement of Intraoperative Irrigation Fluid Absorption and Perioperative cfDNA Profiling
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhiping Wang
Colorectal Cancer, Liver Metastases
ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer
The goal of this clinical trial is to compare in resectable colorectal cancer liver metastasis patients.The main question it aims to answer is whether the 3-year progression-free survival rate (PFS) of "watching and waiting" is…
- Conditions
- Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Chemotherapy Effect
- Trial name
- NCT05815082
- Testing
- Colorectal cancer resection combined with liver metastasis resection., FOLFOX chemotherapy regimen
- Where
- China
- Volunteers
- 490 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Cancer, Early Detection of Cancer
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
- Conditions
- Cancer, Early Detection of Cancer, Circulating Cell-free DNA
- Trial name
- PREVENT (NCT05227534)
- Testing
- OverC multi-cancer detection blood test
- Where
- China
- Volunteers
- 12,500 people, healthy volunteers welcome
- Sponsor
- Guangzhou Burning Rock Dx Co., Ltd.
Unresectable Metastatic Melanoma
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable…
- Trial name
- BRAF SENS (NCT07870265)
- Testing
- Novel CRISPR/Cas12a Electrochemical Bioassay, Reference Standard Molecular Diagnostics (NGS and ddPCR), Serial Peripheral Blood Sampling for Liquid Biopsy
- Where
- Czechia
- Volunteers
- 17 people
- Sponsor
- Masaryk Memorial Cancer Institute
Solid Tumor, Adult, Healthy Donors
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers.
- Conditions
- Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
- Trial name
- NCT00571389
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- BioCytics, Inc.
Neuroblastoma
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
This prospective observational study evaluates serial circulating tumor DNA (ctDNA) and molecular residual disease (MRD) monitoring in patients with neuroblastoma.
- Trial name
- NCT07516678
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Melanoma
Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy
The goal of this clinical trial is to investigate adaptive therapy in late-stage cutaneous melanoma. The main question it aims to answer are: If the patient having breaks in their treatment allows the less resistant cells to…
- Trial name
- DyNAMIc (NCT06470880)
- Testing
- Adaptive Therapy, Standard of Care
- Volunteers
- 40 people
- Sponsor
- The Christie NHS Foundation Trust
Neuroendocrine Neoplasms
Collection of Liquid Biopsy Samples of Neuroendocrine Neoplasms (NEN) Patients - Collection of NET (CollectNET) 2.0, a Study by the BE-FORCE Consortium
The CollectNET 2.0 by BE-FORCE is a prospective, multicentric, interventional study in which liquid biopsies will be collected from neuroendocrine neoplasms (NEN) patients to create an extensive biobank that will be used for…
- Trial name
- BE-FORCE (NCT06541080)
- Testing
- Shallow Whole Genome Sequencing (sWGS)-GIPXplore, methylation-sensitive restriction enzymes (MSRE)-Single-molecule molecular inversion probes (smMIP)-seq assay
- Where
- 8 sites in Belgium
- Volunteers
- 550 people
- Sponsor
- University Hospital, Antwerp
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
The CR1STAL-Adaptive study is a randomized, open-label, phase II multicenter interventional trial designed to evaluate the safety and efficacy of Ivonescimab (PD-1/VEGF bispecific antibody) combined with docetaxel versus standard…
- Trial name
- NCT06951646
- Testing
- Ivonescimab, Docetaxel, Standard Treatment group
- Where
- 20 sites in China
- Volunteers
- 70 people
- Sponsor
- Second Xiangya Hospital of Central South University
Non Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.
This is an observational study, aiming to investigate whether the ctDNA dynamics analyzed by the K-TrackTM assay could predict early response to Tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung…
- Conditions
- Non Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT06167460
- Where
- Vietnam
- Volunteers
- 50 people
- Sponsor
- Gene Solutions
microRNA, Circulating Tumor Cells
The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy
Among the currently important biomarkers, circulating tumor cells and microRNA (miRNA) have received significant attention. The latter, also translated as micro-ribonucleic acid, is a widely present ribonucleic acid (RNA)…
- Conditions
- microRNA, Circulating Tumor Cells, Immunotherapy
- Trial name
- NCT07260370
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chang Gung Memorial Hospital
Healthy Volunteer, Prostate Cancer
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes.
- Conditions
- Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer
- Trial name
- NCT04354064
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Oropharyngeal Squamous Cell Carcinoma, Human Papillomavirus (HPV)
The Role of Circulating Tumour DNA in Head and Neck Cancer
Cancers of the throat, oropharyngeal squamous cell carcinoma (OPSCC), are highly prevalent across Scotland. Over the past 10 years, both global and Scottish cases of OPSCC have increased, particularly those associated with human…
- Trial name
- NCT05539638
- Where
- 5 sites in United Kingdom
- Volunteers
- 250 people
- Sponsor
- University of Edinburgh